The Supreme Court's blockbuster case over access to abortion drug mifepristone could upend the way the Food and Drug Administration broadly regulates medicines and other products.
Why it matters: Courts for years have given the FDA latitude to make judgments about health and safety based on scientific studies, but a challenge the justices hear Tuesday could set a precedent for courts to substitute their own conclusions for agency decisions.
